Glucocorticoid receptor binding: A biphasic dependence on molecular size as revealed by the bilinear LinBiExp model

Steroids

Volumn 73, Issue 2, 2008, Pages 193-208

  Buchwald, Peter ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Binding affinity; Fluorination; Glucocorticoid; Molecular size; Structure activity relationship

Indexed keywords

BETAMETHASONE DERIVATIVE; BUDESONIDE; CARBENE; CLOBETASOL PROPIONATE; FLUNISOLIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR; HALOGEN; HYDROCORTISONE; HYDROGEN; LIGAND; LOTEPREDNOL ETABONATE; MOMETASONE FUROATE; PREDNISOLONE; PROGESTERONE; TRIAMCINOLONE ACETONIDE;

ARTICLE; BINDING AFFINITY; BINDING SITE; CALCULATION; DRUG BINDING; DRUG STRUCTURE; HALOGENATION; MOLECULAR SIZE; NONHUMAN; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THERMODYNAMICS;

ADRENAL CORTEX HORMONES; ANIMALS; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; RECEPTORS, GLUCOCORTICOID; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 37649006828     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2007.10.001     Document Type: Article

References (111)

1. Schimmer B.P., and Parker K.L. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman J.G., and Limbird L.E. (Eds). Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. (1996), McGraw-Hill, New York 1459-1485
2. Avery M.A., and Woolfrey J.R. Anti-inflammatory steroids. In: Abraham D.J. (Ed). Burger's medicinal chemistry and drug discovery, cardiovascular agents and endocrines. 6th ed. vol. 3 (2003), Wiley, New York 747-853
3. Bodor N., and Buchwald P. Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids. Curr Pharm Des 12 25 (2006) 3241-3260
4. Martindale W. The extra pharmacopoeia. 31st ed. (1996), Pharmaceutical Press, London
5. Barnes P.J. Therapeutic strategies for allergic diseases. Nature 402 Suppl. (1999) B31-B38
6. Jensen E.V., Suzuki T., Kawashima T., Stumpf W.E., Jungblut P.W., and DeSombre E.R. A two-step mechanism for the interaction of estradiol with rat uterus. Proc Natl Acad Sci U S A 59 2 (1968) 632-638
7. Hollenberg S.M., Weinberger C., Ong E.S., Cerelli G., Oro A., Lebo R., et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 318 6047 (1985) 635-641
8. Baraniuk J.N. Molecular actions of glucocorticoids: an introduction. J Allergy Clin Immunol 97 (1996) 141-142
9. Barnes P.J. Molecular mechanisms of corticosteroids in allergic diseases. Allergy 56 (2001) 928-936
10. Kumar R., and Thompson E.B. The structure of the nuclear hormone receptors. Steroids 64 (1999) 310-319
11. Lu N.Z., Wardell S.E., Burnstein K.L., Defranco D., Fuller P.J., Giguere V., et al. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev 58 4 (2006) 782-797
12. Overington J.P., Al-Lazikani B., and Hopkins A.L. How many drug targets are there?. Nat Rev Drug Discov 5 12 (2006) 993-996
13. Bledsoe R.K., Montana V.G., Stanley T.B., Delves C.J., Apolito C.J., McKee D.D., et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110 (2002) 93-105
14. Kauppi B., Jakob C., Färnegårdh M., Yang J., Ahola H., Alarcon M., et al. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem 278 25 (2003) 22748-22754
15. Falkenstein E., Tillmann H.-C., Christ M., Feuring M., and Wehling M. Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacol Rev 52 4 (2000) 513-556
16. Norman A.W., and Mizwicki M.T. Norman DPG. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 1 (2004) 27-41
17. Maier C., Runzler D., Schindelar J., Grabner G., Waldhausl W., Kohler G., et al. G-protein-coupled glucocorticoid receptors on the pituitary cell membrane. J Cell Sci 118 Pt 15 (2005) 3353-3361
18. Löwenberg M., Verhaar A.P., van den Brink G.R., and Hommes D.W. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. Trends Mol Med 13 4 (2007) 158-163
19. Kenakin T.P. A pharmacology primer. Theory, applications, and methods. 2nd ed. (2006), Academic Press, Burlington MA
20. Schaaf M.J., and Cidlowski J.A. Molecular determinants of glucocorticoid receptor mobility in living cells: the importance of ligand affinity. Mol Cell Biol 23 6 (2003) 1922-1934
21. Kelly H.W. Establishing a therapeutic index for the inhaled corticosteroids: part I Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol 102 (1998) S36-S51
22. Rohdewald P.J. Comparison of clinical efficacy of inhaled glucocorticoids. Arzneim-Forsch/Drug Res 48 II (1998) 789-796
23. Derendorf H., Hochhaus G., Meibohm B., Möllmann H., and Barth J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 101 (1998) S440-S446
24. Rohatagi S., Arya V., Zech K., Nave R., Hochhaus G., Jensen K., et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 43 (2003) 365-378
25. Mager D.E., Moledina N., and Jusko W.J. Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation. J Pharm Sci 92 (2003) 1521-1525
26. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: NIH, NHLBI; 1997.
27. Buchman A.L. Side effects of corticosteroid therapy. J Clin Gastroenterol 33 4 (2001) 289-294
28. Lipworth B.J. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 159 (1999) 941-955
29. Allen D.B. Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol 106 Suppl. (2000) S179-S190
30. Perry R.J., Findlay C.A., and Donaldson M.D.C. Cushing's syndrome, growth impairment, and occult adrenal suppression associated with intranasal steroids. Arch Dis Child 87 (2002) 45-48
31. Israel E., Banerjee T.R., Fitzmaurice G.M., Kotlov T.V., LaHive K., and LeBoff M.S. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 345 13 (2001) 941-947
32. Rosen J., and Miner J.N. The search for safer glucocorticoid receptor ligands. Endocr Rev 26 3 (2005) 452-464
33. Boushey H.A. Inhaled corticosteroid therapy for asthma: therapeutic and toxic potentials. Am J Med 108 (2000) 338-340
34. Brattsand R. Development of inhaled steroids: past, present, and prospects. In: Dalby R.N., Byron P.R., Peart J., and Farr S.J. (Eds). Respiratory drug delivery vol. III (2002), Virginia Commonwealth University, Richmond, VA 1-14
35. Volcheck G.W., and O'Connell E.J. Anti-inflammatory drugs for controlling asthma. Postgrad Med 104 (1998) 127-136
36. Chen F., Kearney T., Robinson S., Daley-Yates P.T., Waldron S., and Churchill D.R. Cushing's syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone. Sex Transm Infect 75 (1999) 274
37. Gupta S.K., and Dubé M.P. Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy. Clin Infect Dis 35 (2002) E69-E71
38. Raaska K., Niemi M., Neuvonen M., Neuvonen P.J., and Kivistö K.T. Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. Clin Pharmacol Ther 72 (2002) 362-369
39. Bolland M.J., Bagg W., Thomas M.G., Lucas J.A., Ticehurst R., and Black P.N. Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother 38 (2004) 46-49
40. Martin R.J., Szefler S.J., Chinchilli V.M., Kraft M., Dolovich M., Boushey H.A., et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 165 (2002) 1377-1383
41. Buchwald P. General linearized biexponential model for QSAR data showing bilinear-type distribution. J Pharm Sci 94 11 (2005) 2355-2379
42. Buchwald P. A general bilinear model to describe growth or decline time-profiles. Math Biosci 205 1 (2007) 108-136
43. Buchwald P., and Bodor N. Soft quaternary anticholinergics: comprehensive QSAR with a linearized biexponential (LinBiExp) model. J Med Chem 49 3 (2006) 883-891
44. Wolff M.E., Baxter J.D., Kollman P.A., Lee D.L., Kuntz I.D., Bloom E., et al. Nature of steroid-glucocorticoid receptor interactions: thermodynamic analysis of the binding reaction. Biochemistry 17 (1978) 3201-3208
45. Dahlberg E., Thalén A., Brattsand R., Gustafsson J.-A., Johansson U., Roempke K., et al. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16α, 17α-acetal-substituted glucocorticoids. Mol Pharmacol 25 (1984) 70-78
46. Ponec M., Kempenaar J., Shroot B., and Caron J.-C. Glucocorticoids: binding affinity and lipophilicity. J Pharm Sci 75 (1986) 973-975
47. Wojnar R.J., Varma R.K., Free C.A., Millonig R.C., Karanewsky D., and Lutsky B.N. Androstene-17-thioketals. 1st communication: Glucocorticoid receptor binding, antiproliferative and antiinflammatory activities of some novel 20-thiasteroids (androstene-17-thioketals). Arzneim-Forsch/Drug Res 36 (1986) 1782-1787
48. Derendorf H., Hochhaus G., Möllmann H., Barth J., Krieg M., Tunn S., et al. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. J Clin Pharmacol 33 (1993) 115-123
49. Barnes P.J., Pedersen S., and Busse W.W. Efficacy and safety of inhaled corticosteroids New Developments. Am J Respir Crit Care Med 157 (1998) S1-S53
50. Smith C.L., and Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneim-Forsch/Drug Res 48 II (1998) 956-960
51. Bodor N. Androstene derivatives. U.S. Patent 5,981,517; 1999 November 9.
52. Biggadike K., Angell R.M., Burgess C.M., Farrell R.M., Hancock A.P., Harker A.J., et al. Selective plasma hydrolysis of glucocorticoid γ-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism. J Med Chem 43 (2000) 19-21
53. Thalén A., Andersson P.H., Andersson P.T., Axelsson B., Edsbäcker S., and Brattsand R. Prospects for developing inhaled steroids with extrahepatic metabolism-"soft steroids". In: Schleimer R.P., O'Byrne P.M., Szefler S.J., and Brattsand R. (Eds). Inhaled steroids in asthma optimizing effects in the airways (2002), Marcel Dekker, New York 521-537
54. Brattsand R. A pharmacologist's view based on experiences from the budesonide project. In: Schleimer R.P., O'Byrne P.M., Szefler S.J., and Brattsand R. (Eds). Inhaled steroids in asthma optimizing effects in the airways (2002), Marcel Dekker, New York 3-32
55. Mager D.E., and Jusko W.J. Quantitative structure-pharmacokinetic/pharmacodynamic relationships of corticosteroids in man. J Pharm Sci 91 (2002) 2441-2451
56. Hammer S., Spika I., Sippl W., Jessen G., Kleuser B., Höltje H.-D., et al. Glucocorticoid receptor interactions with glucocorticoids: evaluation by molecular modeling and functional analysis of glucocorticoid receptor mutants. Steroids 68 (2003) 329-339
57. Buchwald P., and Bodor N. Soft glucocorticoid design: structural elements and physicochemical parameters determining receptor-binding affinity. Pharmazie 59 (2004) 396-404
58. Valotis A., Neukam K., Elert O., and Högger P. Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. J Pharm Sci 93 (2004) 1337-1350
59. Würthwein G., Rehder S., and Rohdewald P. Lipophilicity and receptor affinity of glucocorticoids. Pharm Ztg Wiss 4 (1992) 161-167
60. Park K.-K., Ko D.-H., You Z., Heiman A.S., and Lee H.J. Synthesis and pharmacological evaluations of new steroidal anti-inflammatory antedrugs: 9α-Fluoro-11β,17α,21-trihydroxy-3,20-dioxo-pregna-1 4-diene-16α-carboxylate (FP16CM) and its derivatives. Steroids 71 1 (2006) 83-89
61. Bodor N. Design of biologically safer chemicals based on retrometabolic concepts. In: DeVito S.C., and Garrett R.L. (Eds). Designing safer chemicals green chemistry for pollution prevention (1996), ACS, Washington, DC 84-115
62. Hochhaus G., Druzgala P., Hochhaus R., Huang M.-J., and Bodor N. Glucocorticoid activity and structure activity relationship in a series of some novel 17α-ether-substituted steroids: influence of 17α-substituents. Drug Design Deliv 8 (1991) 117-125
63. Druzgala P., Hochhaus G., and Bodor N. Soft drugs 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem 38 (1991) 149-154
64. Bodor N., and Buchwald P. Design and development of a soft corticosteroid, loteprednol etabonate. In: Schleimer R.P., O'Byrne P.M., Szefler S.J., and Brattsand R. (Eds). Inhaled steroids in asthma optimizing effects in the airways (2002), Marcel Dekker, New York 541-564
65. 50) of an enzymatic reaction. Biochem Pharmacol 22 23 (1973) 3099-3108
66. Andrews P.R., Craik D.J., and Martin J.L. Functional group contributions to drug-receptor interactions. J Med Chem 27 (1984) 1648-1657
67. Heiman A.S., Ko D.-H., Chen M., and Lee H.J. New steroidal anti-inflammatory antedrugs: methyl 3,20-dioxo-9α-fluoro-11β,17α,21-trihydroxy-1,4-pregnadiene-16α-carboxylate and methyl 21-acetyloxy-3,20-dioxo-11β,17α-dihydroxy-9α-fluoro-1,4-pregnadiene-16α-carboxylate. Steroids 62 (1997) 491-499
68. Wagner B.L., Pollio G., Giangrande P., Webster J.C., Breslin M., Mais D.E., et al. The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestins. Endocrinology 140 3 (1999) 1449-1458
69. Miner J.N., Tyree C., Hu J., Berger E., Marschke K., Nakane M., et al. A nonsteroidal glucocorticoid receptor antagonist. Mol Endocrinol 17 1 (2003) 117-127
70. Belvisi M.G., Bundschuh D.S., Stoeck M., Wicks S., Underwood S., Battram C.H., et al. Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma. J Pharmacol Exp Ther 314 2 (2005) 568-574
71. Hudson A.R., Roach S.L., Higuchi R.I., Phillips D.P., Bissonnette R.P., Lamph W.W., et al. Synthesis and characterization of nonsteroidal glucocorticoid receptor modulators for multiple myeloma. J Med Chem 50 19 (2007) 4699-4709
72. Buchwald P., and Bodor N. Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters. J Med Chem 42 (1999) 5160-5168
73. Buchwald P. Complexation thermodynamics of cyclodextrins in the framework of a molecular size-based model for nonassociative organic liquids that includes a modified hydration-shell hydrogen-bond model for water. J Phys Chem B 106 (2002) 6864-6870
74. Buchwald P., Einstein B., and Bodor N. QSAR study of 2,3-benzodiazepin-4(thi)one- and 1, 2-phthalazine-related negative allosteric modulators of the AMPA receptor: a structural descriptors-based reassessment. QSAR Comb Sci 24 3 (2005) 325-331
75. Dewar M.J.S., Zoebisch E.G., Healy E.F., and Stewart J.J.P. AM1: a new general purpose quantum mechanical molecular model. J Am Chem Soc 107 (1985) 3902-3909
76. Bodor N., Harget A.J., and Philips E.W. Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach. J Med Chem 26 (1983) 318-328
77. Lewis J.G., Bagley C.J., Elder P.A., Bachmann A.W., and Torpy D.J. Plasma free cortisol fraction reflects levels of functioning corticosteroid-binding globulin. Clin Chim Acta 359 1-2 (2005) 189-194
78. Hammond G.L. Determinants of steroid hormone bioavailability. Biochem Soc Trans 25 2 (1997) 577-582
79. Cramer III R.D., Patterson D.E., and Bunce J.D. Comparative molecular field analysis (CoMFA) 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110 (1988) 5959-5967
80. Good A.C., So S.S., and Richards W.G. Structure-activity relationships from molecular similarity matrices. J Med Chem 36 4 (1993) 433-438
81. Maw H.H., and Hall L.H. E-state modeling of corticosteroids binding affinity validation of model for small data set. J Chem Inf Comput Sci 41 5 (2001) 1248-1254
82. Stouch T.R., and Jurs P.C. Computer-aided studies of the structure-activity relationship between the structure of some steroids and their antiinflammatory activity. J Med Chem 29 (1986) 2125-2136
83. Zeelen F.J. QSAR of steroids. Quant Struct-Act Relat 5 (1986) 131-137
84. Buchwald P., and Bodor N. Octanol-water partition: searching for predictive models. Curr Med Chem 5 (1998) 353-380
85. Teague S.J. Implications of protein flexibility for drug discovery. Nat Rev Drug Discov 2 (2003) 527-541
86. Nilsson S., and Koehler K.F. Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology. Basic Clin Pharmacol Toxicol 96 1 (2005) 15-25
87. Kuntz I.D., Chen K., Sharp K.A., and Kollman P.A. The maximal affinity of ligands. Proc Natl Acad Sci U S A 96 (1999) 9997-10002
88. Andrews P.R. The role of functional groups in drug-receptor interactions. In: Wermuth C.G. (Ed). The practice of medicinal chemistry (1996), Academic Press, London 345-365
89. Hajduk P.J. Fragment-based drug design: how big is too big?. J Med Chem 49 24 (2006) 6972-6976
90. Wermuth C.G. Molecular variations based on isosteric replacements. In: Wermuth C.G. (Ed). The practice of medicinal chemistry (1996), Academic Press, London 203-237
91. Seeley D.H., Wang W.Y., and Salhanick H.A. Molecular interactions of progesterone analogues with rabbit uterine cytoplasmic receptor. J Biol Chem 257 (1982) 13359-13366
92. Issar M., Sahasranaman S., Buchwald P., and Hochhaus G. Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J 27 3 (2006) 511-516
93. Funder J.W., Adam W.R., Mantero F., Kraft N., and Ulick S. The etiology of a syndrome of factitious mineralocorticoid excess: a steroid-containing nasal spray. J Clin Endocrinol Metab 49 6 (1979) 842-846
94. Diederich S., Eigendorff E., Burkhardt P., Quinkler M., Bumke-Vogt C., Rochel M., et al. 11β-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab 87 12 (2002) 5695-5701
95. Czock D., Keller F., Rasche F.M., and Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44 1 (2005) 61-98
96. Rohatagi S., Appajosyula S., Derendorf H., Szefler S., Nave R., Zech K., et al. Risk-benefit value of inhaled corticosteroids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 44 (2004) 37-47
97. Rose G.D., and Wolfenden R. Hydrogen bonding, hydrophobicity, packing, and protein folding. Annu Rev Biophys Biomol Struct 22 (1993) 381-415
98. Lumry R., and Rajender S. Enthalpy-entropy compensation phenomena in water solutions of proteins and small molecules: a ubiquitous property of water. Biopolymers 9 (1970) 1125-1227
99. Grunwald E., and Steel C. Solvent reorganization and thermodynamic enthalpy-entropy compensation. J Am Chem Soc 117 21 (1995) 5687-5692
100. Liu L., and Guo Q.-X. Isokinetic relationship, isoequilibrium relationship, and enthalpy-entropy compensation. Chem Rev 101 (2001) 673-695
101. Némethy G., and Scheraga H.A. Structure of water and hydrophobic bonding in proteins I. A model for the thermodynamic properties of liquid water. J Chem Phys 36 (1962) 3382-3400
102. Grant D.J.W., and Higuchi T. Solubility behavior of organic compounds (1990), Wiley-Interscience, New York
103. Jeffrey G.A., and Saenger W. Hydrogen bonding in biological structures (1994), Springer, Berlin
104. Smith J.D., Cappa C.D., Wilson K.R., Messer B.M., Cohen R.C., and Saykally R.J. Energetics of hydrogen bond network rearrangements in liquid water. Science 306 5697 (2004) 851-853
105. Fersht A.R., Shi J.-P., Knill-Jones J., Lowe D.M., Wilkinson A.J., Blow D.M., et al. Hydrogen bonding and biological specificity analysed by protein engineering. Nature 314 (1985) 235-238
106. Fersht A.R. The hydrogen bond in molecular recognition. Trends Biochem Sci 12 (1987) 301-304
107. Shirley B.A., Stanssens P., Hahn U., and Pace C.N. Contribution of hydrogen bonding to the conformational stability of ribonuclease T1. Biochemistry 31 (1992) 725-732
108. Stapley B.J., and Doig A.J. Hydrogen bonding interactions between glutamine and asparagine in α-helical peptides. J Mol Biol 272 (1997) 465-473
109. Bodor N., and Buchwald P. Molecular size based approach to estimate partition properties for organic solutes. J Phys Chem B 101 (1997) 3404-3412
110. Elmore S.W., Coghlan M.J., Anderson D.D., Pratt J.K., Green B.E., Wang A.X., et al. Nonsteroidal selective glucocorticoid modulators: the effect of C-5 alkyl substitution on the transcriptional activation/repression profile of 2,5-dihydro-10-methoxy-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines. J Med Chem 44 25 (2001) 4481-4491
111. Coghlan M.J., Jacobson P.B., Lane B., Nakane M., Lin C.W., Elmore S.W., et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol 17 5 (2003) 860-869